These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23194056)

  • 1. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
    Dunavin NC; Wei L; Elder P; Phillips GS; Benson DM; Hofmeister CC; Penza S; Greenfield C; Rose KS; Rieser G; Merritt L; Ketcham J; Heerema N; Byrd JC; Devine SM; Efebera YA
    Leuk Lymphoma; 2013 Aug; 54(8):1658-64. PubMed ID: 23194056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
    Venner CP; Connors JM; Sutherland HJ; Shepherd JD; Hamata L; Mourad YA; Barnett MJ; Broady R; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Nitta J; Power MM; Toze CL; Smith CA; Song KW
    Leuk Lymphoma; 2011 Jan; 52(1):34-41. PubMed ID: 21133716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
    Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
    Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Gay F; Magarotto V; Crippa C; Pescosta N; Guglielmelli T; Cavallo F; Pezzatti S; Ferrari S; Liberati AM; Oliva S; Patriarca F; Offidani M; Omedé P; Montefusco V; Petrucci MT; Giuliani N; Passera R; Pietrantuono G; Boccadoro M; Corradini P; Palumbo A
    Blood; 2013 Aug; 122(8):1376-83. PubMed ID: 23775712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
    Chim CS; Lie AK; Chan EY; Liu HS; Lau CW; Yip SF; Sim J; Wan TS; Ma ES; Liang R; Tse E; Kwong YL;
    J Hematol Oncol; 2012 Jun; 5():28. PubMed ID: 22682027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
    Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA
    Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
    Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
    Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Moreau P; Avet-Loiseau H; Facon T; Attal M; Tiab M; Hulin C; Doyen C; Garderet L; Randriamalala E; Araujo C; Lepeu G; Marit G; Caillot D; Escoffre M; Lioure B; Benboubker L; Pégourié B; Kolb B; Stoppa AM; Fuzibet JG; Decaux O; Dib M; Berthou C; Chaleteix C; Sebban C; Traullé C; Fontan J; Wetterwald M; Lenain P; Mathiot C; Harousseau JL
    Blood; 2011 Nov; 118(22):5752-8; quiz 5982. PubMed ID: 21849487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of newly diagnosed myeloma.
    Palumbo A; Rajkumar SV
    Leukemia; 2009 Mar; 23(3):449-56. PubMed ID: 19005483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating novel therapies in the transplant paradigm.
    Harousseau JL
    Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.